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OBJECTIVES: Acromegaly is a rare disease with an estimated incidence of 2.5 cases
per million (cpm) and a prevalence of 50-60 (cpm) per year according to Spanish
national data. Somatuline Autogel (Ipsen property) and Sandostatin LAR (Novartis
property) are associated with similar efficacy and together they represent more
than 90% of long-acting somatostatin analogs sales in Spain. Somatuline Autogel
has been approved of an injection extended dosing interval for 6 or 8 weeks with
the dose of 120mg. This study is aimed to estimate the potential budgetary conse-
quences of increasing the use of Somatuline Autogel in the treatment of acromeg-
aly in Spain.METHODS: A budget impact model was developed to compare annual
treatment costs of acromegaly patients with either Somatuline Autogel and San-
dostatin LAR, including drug acquisition costs and administration costs. Disease
prevalence and IMS sales data were used to estimate total number of patients using
both treatments, and the potential budget impact of increasing Somatuline Autogel
was calculated under different scenarios based on the proportion of patients using
different dose ranges. RESULTS: Overall treatment costs were 11,857€ and 12,165€
per patient/year for Somatuline Autogel and Sandostatin LAR respectively
(monthly treatment), as a result of the higher acquisition cost and administration
costs of the latter. Furthermore, assuming that 30% of patients with Somatuline
Autogel may benefit of the extended dose interval (every 6 or 8 weeks), mean cost
savings per patient may rise to 2,019€ (10,147€ vs. 12,165€). When applying these
patient-level cost savings with Somatuline Autogel to total treated patients, acro-
megaly treatment costs could be reduced by 0.3 M€ to 1.2 M€ by increasing the
proportion of patients treated with Somatuline Autogel from current 42% up to 50%
and 70% respectively in Spain. CONCLUSIONS: Using Somatuline Autogel in acro-
megaly patients is associated with favorable economic outcomes when compared
to other long-acting somatostatin analogs in Spain.
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OBJECTIVES: According to World Federation of Hemophilia, more than 90% of cost
of hemophilia treatment is the cost of factor replacement. Currently, 13 different
Factor VIII products are available in Turkish market. These are classified as bio-
equivalent and these products are neither included in a willingness to pay thresh-
old nor in a pharmacoeconomic analysis before the reimbursement decision. The
aim of this study is determining the budget impact of possible cost minimization
strategies in reimbursement of Factor VIII products via investigating current reim-
bursement conditions and evaluation of possible ways for inserting cost minimi-
zation from the Payer’s perspective. METHODS: IMS data (September 2009-2010) is
evaluated for Factor VIII products in Turkish market. Current reimbursed prices are
evaluated for determination of particular patterns of reimbursement. Annual vol-
ume of Factor VIII consumption and annual cost of Factor VIII consumption are
linked and re-defined for cost minimization estimates in Microsoft 2003 Excel.
TreeAgePro2011 is used for calculations and decision tree structuring. RESULTS:
Annual consumption of Factor VIII products constitutes 128,319,000 IU and an
annual cost of 129,806,872.88 TL. The Payer can imply cost minimization strategies
(change reimbursement strategies and/or eliminating waste) resulting in gradual
reduction from total expenditure as 2.6% (3,390,029.43 TL/year), 2.8% (3,610,300.16
TL/year), 5.7% (7,357,325.35 TL/year), 18.9% (24,595,818.19 TL/year) and 20.8%
(27,059,457.55 TL/year). CONCLUSIONS: Payer may apply following steps for cost
minimization, therefore obtaining a positive budget impact for Factor VIII spending
in Turkey; Step1: Evaluation of all Factor VIII products according to the reimbursed
prices; Step2: Classification of reimbursement pattern for each product; Step3:
Standardization of reimbursement patterns for all products; Step4: Promotion of
differentiation for availability of forms; Step5: Monitoring annual budget impact
effect of all previous steps.
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OBJECTIVES: To examine the most common reasons for inpatient admissions
among fibromyalgia patients who initiated duloxetine or pregabalin. METHODS:
Using a large US national commercial healthcare claims database, fibromyalgia
patients aged 18-64 who initiated duloxetine or pregabalin in 2006 were identified.
All patients included had 12-month continuous enrollment before and after the
initiation, and at least 31 total duloxetine or pregabalin supply days over the 12-
month post-index period. Propensity scoring was applied to construct duloxetine
and pregabalin cohorts with similar demographics, pre-index clinical and eco-
nomic characteristics, and pre-index treatment patterns. Reasons for inpatient
admissions between the cohorts were examined. Logistic regressions were used to
assess the contribution of duloxetine versus pregabalin initiation to the top rea-
sons for inpatient admissions controlling for cross-cohort differences. RESULTS:
Per our study design, duloxetine (n3,711) and pregabalin (n4,111) patients had
similar demographics with a mean age of 51 years and 83% females. Both cohorts
had similar co-morbidities, with cardiovascular disease being the most common.
Duloxetine and pregabalin patients, by the study design, also had similar total
health care costs over the 12-month pre-index period ($18,970 vs. $19,019, p0.994)
with 22% contributed by inpatient care. Eight of the top 10 reasons for inpatient
admissions over the 12-months post-index period were the same for both groups
with intervertebral disc disorder, osteoarthritis of lower leg, and chest pain being
the top 3 leading reasons. Controlling for cross-cohort differences, duloxetine pa-
tients were at a significantly lower risk for hospitalizations due to intervertebral
disc disorder or major depression disorder (MDD) (odds ratios0.44, 0.81, respec-
tively; both p0.0001).CONCLUSIONS:Among similar commercially-insured fibro-
myalgia patients who initiated duloxetine or pregabalin, the leading reasons for
inpatient admissions were somewhat different between groups. Compared to pre-
gabalin initiators, duloxetine initiators tended to be less likely to have inpatient
admissions due to intervertebral disc disorder or MDD.
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OBJECTIVES: To examine the most common reasons for primary or specialty care
visits among fibromyalgia patients initiated duloxetine or pregabalin. METHODS:
Using a large US commercially-insured administrative claims database, we exam-
ined fibromyalgia patients aged 18-64 who initiated duloxetine or pregabalin in
2006. All patients were required to have 12 months of continuous enrollment prior
to and after the initiation. Applying propensity scoring, we constructed the dulox-
etine and pregabalin cohorts to have similar demographics, comorbid medical
conditions, prior healthcare utilization and costs, and prior medication use. Using
the first diagnosis recorded in all outpatient claims, we examined the reasons for
primary vs. specialty care over the 12-month post-index period. Controlling for
cross-cohort differences, we assess the impact of duloxetine vs. pregabalin initia-
tion on the top reasons for primary care or specialty care visits via logistic
regressions. RESULTS: The study sample included 3,711 duloxetine and 4,111 pre-
gabalin patients with a mean age of 51 years and around $19,000 prior total health-
care costs. Duloxetine and pregabalin patients shared 8 (9) out of the 10 top reasons
for primary (specialty) care visits, with most of the prevalence rates/10,000 being
higher (lower) among the duxeteine patients. Controlling for cross-cohort differ-
ences, duloxetine patients were more likely to have a primary care visit due to
disorder of soft tissue, essential hypertension, or other general symptoms (odds
ratios1.12, 1.16, 1.14, respectively), but less likely to go to specialty care due to
disorder of soft tissue, nonspecific backache/other back/neck pain, or interverte-
bral disc disorder (odds ratios0.83, 0.69, 0.63, respectively) (all p0.05).
CONCLUSIONS: Among commercially-insured fibromyalgia patients who initiated
duloxetine or pregabalin, the most common reason for primary or specialty care
was somewhat different. Duloxetine initiators tended to be less likely to use spe-
cialty care, and more likely to use primary care for disorder of soft tissue.
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OBJECTIVES: To examine the most common reasons for physician office visits,
outpatient hospital visits, and emergency room (ER) visits among fibromyalgia
patients who initiated duloxetine or pregabalin.METHODS: Commercially-insured
fibromyalgia patients aged 18-64 who initiated duloxetine or pregabalin in 2006
were examined. All patients selected had continuous enrollment during the 12
months before and after the initiation. Each patient was classified into the dulox-
tetine or pregabalin cohort based on the index medication, and both cohorts were
constructed via propensity scoring to have similar demographics, comoribidities,
prior healthcare costs, and prior pain-related medication use. Reasons for physi-
cian office, outpatient hospital, and ER visits over the 12 months post-index period
were examined for both cohorts. The impact of duloxetine vs. pregabalin initiation
on the top reasons leading to physician office, outpatient hospital, or ER visits was
examined via logistic regressions controlling for the cross-cohort differences.
RESULTS: A total of 3711 duloxetine and 4111 pregabalin patients were included
with a mean age of 51 years and 83% being female. Duloxetine and pregabalin
patients had similar total healthcare costs ($18,970 vs. $19,019, p0.994) over the 12
months pre-index period, with 52-53% contributed by the outpatient care. Both
groups shared 9 out of the top 10 reasons for physician office visits, 7 of the 10 most
common reasons for outpatient hospital visits, and 8 of the top 10 reasons for ER
visits. Controlling for cross-cohort differences, duloxetine patients were less likely
to have a physician office visit due to nonspecific backache/other back/neck pain
but more likely to go to the ER due to other general symptoms (odds ratios0.91,
1.43, respectively, both p0.001). CONCLUSIONS: Among commercially-insured
fibromyalgia patients who had similar demographic and clinical characteristics
and initiated duloxetine or pregabalin in 2006, the leading reasons were somewhat
different for physician office visits, outpatient hospital or ER visits.
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STRIVING FOR AFFORDABLE TREATMENTS WITHIN THE GREEK ENVIRONMENT:
DO EPOETIN BIOSIMILARS HELP?
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